BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29692212)

  • 1. Use of glucocorticoids in patients with COPD exacerbations in China: a retrospective observational study.
    Zhang J; Zheng J; Huang K; Chen Y; Yang J; Yao W
    Ther Adv Respir Dis; 2018; 12():1753466618769514. PubMed ID: 29692212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of medical expenditure with nebulized budesonide versus systemic corticosteroids in hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease in China.
    Zhang J; Yao W; You X; Liu T; Liu Y
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1195-1207. PubMed ID: 31213797
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimization of Nebulized Budesonide in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
    Zhang R; Zhu J; Liu Y; Li Y; Liu W; Zhang M; Chen B; Zhu S
    Int J Chron Obstruct Pulmon Dis; 2020; 15():409-415. PubMed ID: 32161453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes Of Using Nebulized Budesonide As The Initial Treatment For Acute Exacerbations Of Chronic Obstructive Pulmonary Disease: A Post-Hoc Analysis.
    Zheng JP; Zhang J; Ma LJ; Chen P; Huang M; Ou XM; Zhao ZW; Jiang SJ; Cao J; Yao W
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2725-2731. PubMed ID: 31819404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, controlled multicentric study of inhaled budesonide and intravenous methylprednisolone in the treatment on acute exacerbation of chronic obstructive pulmonary disease.
    Ding Z; Li X; Lu Y; Rong G; Yang R; Zhang R; Wang G; Wei X; Ye Y; Qian Z; Liu H; Zhu D; Zhou R; Zhu K; Ni R; Xia K; Luo N; Pei C
    Respir Med; 2016 Dec; 121():39-47. PubMed ID: 27888990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of a standardized order set reduces systemic corticosteroid dose and length of stay for individuals hospitalized with acute exacerbations of COPD: a cohort study.
    Gulati S; Zouk AN; Kalehoff JP; Wren CS; Davison PN; Kirkpatrick DP; Bhatt SP; Dransfield MT; Wells JM
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2271-2278. PubMed ID: 30100717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Clinical Outcomes Between Nebulized and Systemic Corticosteroids in the Treatment of Acute Exacerbation of COPD in China (CONTAIN Study): A Post Hoc Analysis.
    Chen Y; Liu Y; Zhang J; Yao W; Yang J; Li F; Lu L; Zheng J; Han X; Xu JF
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2343-2353. PubMed ID: 33061352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.
    Jones R; Martin J; Thomas V; Skinner D; Marshall J; Stagno d'Alcontres M; Price D
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2445-2454. PubMed ID: 28860739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Chinese medicine on patients with acute exacerbations of COPD: study protocol for a randomized controlled trial.
    Zhang H; Li J; Yu X; Li S; Wang H; Ruan H; Si Y; Xie Y; Wang M
    Trials; 2019 Dec; 20(1):735. PubMed ID: 31842969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease.
    Woods JA; Wheeler JS; Finch CK; Pinner NA
    Int J Chron Obstruct Pulmon Dis; 2014; 9():421-30. PubMed ID: 24833897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
    Perrone V; Sangiorgi D; Buda S; Degli Esposti L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD.
    Moretti M; Fagnani S
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2319-25. PubMed ID: 26604731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
    Zheng J; Baldi S; Zhao L; Li H; Lee KH; Singh D; Papi A; Grapin F; Guasconi A; Georges G
    Respir Res; 2021 Mar; 22(1):90. PubMed ID: 33757520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of Xuebijing injection and its influence on immunomodulation in acute exacerbations of chronic obstructive pulmonary disease: study protocol for a randomized controlled trial.
    Xie S; Yan P; Yao C; Yan X; Huo Y; Zhang J; Liu S; Feng Z; Shang H; Xie L
    Trials; 2019 Feb; 20(1):136. PubMed ID: 30777117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early COPD Exacerbation Treatment with Combination of ICS and LABA for Patients Presenting with Mild-to-Moderate Worsening of Dyspnea.
    Bourbeau J; Sedeno MF; Metz K; Li PZ; Pinto L
    COPD; 2016 Aug; 13(4):439-47. PubMed ID: 26752024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exacerbation recovery patterns in newly diagnosed or maintenance treatment-naïve patients with COPD: secondary analyses of TICARI 1 trial data.
    Mannino DM; Clerisme-Beaty EM; Franceschina J; Ting N; Leidy NK
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1515-1525. PubMed ID: 29785101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical investigation on the related factors for the application of systemic glucocorticoids in patients with acute exacerbation of chronic obstructive pulmonary disease with carbon dioxide retention].
    Jiao W; Zhang W; Zhang C; Liu Z; Gan Y; Peng Z; Yan G; Deng X; Xue Q; Wu J
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Sep; 32(9):1061-1066. PubMed ID: 33081891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials.
    Sivapalan P; Rutishauser J; Ulrik CS; Leuppi JD; Pedersen L; Mueller B; Eklöf J; Biering-Sørensen T; Gottlieb V; Armbruster K; Janner J; Moberg M; Lapperre TS; Nielsen TL; Browatzki A; Mathioudakis A; Vestbo J; Schüetz P; Jensen JU
    Respir Res; 2021 May; 22(1):155. PubMed ID: 34020641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment.
    Celli BR; Navaie M; Xu Z; Cho-Reyes S; Dembek C; Gilmer TP
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1019-1031. PubMed ID: 31190787
    [No Abstract]   [Full Text] [Related]  

  • 20. Exacerbation Frequency And Eosinophil Counts Among Patients With COPD Currently Prescribed Triple Therapy.
    Benson VS; Pascoe KC; Siddall J; Small M; Müllerová H
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2711-2723. PubMed ID: 31819403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.